|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We used semiquantitative polymerase chain reaction (RT-PCR) to measure mRNA levels for cytokines before and after IFN beta-1b therapy. mRNA was extracted from mononuclear cells of nine healthy controls and 31 patients with MS. Before therapy, IL-10 and leukemia inhibitory factor (LIF) mRNA levels were elevated in stable MS compared to active MS. Twenty four hours after IFN beta-1b treatment, mRNA levels for IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IFN-gamma, TNF-alpha and LIF had not changed.
|
9345428 |
1996 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found elevated expression of interleukin (IL)-23 and IL-10 in untreated MS patients.
|
18424480 |
2008 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined patterns of Th1/Th2 cytokines (interleukin (IL)-1beta, IL-2, IL-6, IL-12p70, tumor-necrosis factor (TNF)-alpha and interferon-gamma, and IL-4, IL-5 and IL-10, respectively) in the serum of patients with relapsing-remitting MS treated with 250microg interferon-beta 1b or with interferon-beta plus 40mg atorvastatin.
|
18524417 |
2008 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We assessed the relationship of stimulated PBMC-produced IFN-γ, TNF-α, IL-4 and IL-10 in modulating relapse risk using a prospective cohort with established relapsing-remitting MS.
|
24790215 |
2015 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analysed this diallelic polymorphism in patients with multiple sclerosis but did not find any association between a certain -1082 IL10 genotype and susceptibility to or severity of multiple sclerosis.
|
10683520 |
2000 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Transcriptional signature of human pro-inflammatory T<sub>H</sub>17 cells identifies reduced IL10 gene expression in multiple sclerosis.
|
29150604 |
2017 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To study the possible role of tumor necrosis factor-alpha G-308A, interleukin-6 G-174C, interleukin-10 C-592A, C-819T, G-1082A, transforming growth factor (TGF)-beta (codons 10 and 25), and interferon-gamma T+874A polymorphisms in susceptibility to MS in Iranian population, DNA samples from 98 patients and 97 healthy controls were genotyped using polymerase chain reaction-sequence-specific primers.
|
20228669 |
2010 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TLR4 and CD40 co-stimulation synergistically increased the frequency of IL-10-producing but not pro-inflammatory cytokine-producing B cells at MS relapse.
|
29146546 |
2018 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This was surprising as both TLR3 and IL-10 play protective roles in animal models of MS. Interestingly, combination of TLR3 triggering with the other TLRs, enhanced IL-10 through the modulation of its transcription, via interferon (IFN)-β, but independently of IL-27.
|
28617991 |
2017 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This mAb exerted immunosuppressive activity on MS-derived T cell lines through induction and release of high amounts of interleukin-10 and decreased levels of interleukin-12 from activated monocytes providing the biological basis for a potential new treatment for MS and other immune-mediated neurological disorders.
|
23318105 |
2013 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is the first pharmacological assessment of such a broad range of EAE symptoms, and provides support for IL-10 gene therapy as a clinical strategy for the treatment of multiple sclerosis.
|
27189037 |
2017 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
These results indicate that IL-10 regulatory function is impaired in patients with MS.
|
18200504 |
2008 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were striking defects in the induction of Tr1 cells with CD46 costimulation as measured by IL-10 but not IFN-gamma secretion in patients with MS compared with healthy subjects.
|
17099776 |
2006 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS).
|
12220553 |
2003 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The primary progressive MS patients with the low IL-10 expression haplotype showed a trend towards a worse clinical outcome than did patients with medium- or high-expression haplotypes (P = 0.056).
|
12220699 |
2002 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The levels of TNF-a and IL-10 in the serum and CSF at the relieving stage of MS patients were higher than those of healthy individuals, suggest that at relieving stage, MS may be still developing.
|
27831647 |
2016 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The expression of tumor necrosis factor-alpha, interleukin-10 (IL-10) and IL-12 mRNA in CSF MNC did not differ between MS patients with and without active MRI lesions.
|
10416508 |
1999 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The data indicate that IL-10 is not a major susceptibility locus in MS, but in our population it might, however, have a minor role.
|
12458048 |
2002 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The concentration of sCD27 was higher in the NMO group than in the MS (p = 0.082) and CTL (p = 0.002) groups, and there was a positive correlation with CSF IL-6 (p = 0.000) and a negative correlation with IL-10 (p = 0.073).
|
30423585 |
2018 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to determine whether sequence variations in the IL-10 gene were associated with MS susceptibility and progression.
|
12101075 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
The aim of our study was to determine whether sequence variations in the IL-10 gene were associated with MS susceptibility and progression.
|
12101075 |
2003 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The ability of Breg cells to produce IL-10 was at normal levels in both ON patients with high risk and those with low risk of progression to MS. We found no correlation between Breg cell function and the presence of brain white matter lesions by magnetic resonance imaging or CSF oligoclonal bands indicative of ON patients carrying a higher risk of conversion to MS.
|
30452090 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results showed that: 1) CD19+/TNFα+, CD19+/IL-12+ and CD19+/IFNγ+ lymphocytes are significantly increased in primary progressive (PP) compared to secondary progressive (SP), relapsing-remitting (RR), benign (BE) MS and HC; 2) CD19+/IL-6+ lymphocytes are significantly increased in PP, SP and RR compared to BEMS and HC; and 3) CD19+/IL-13+, CD19+/IL-10+, and CD19+/IL-10+/TGFβ+ (Bregs) B lymphocytes are reduced overall in MS patients compared to HC.
|
27412504 |
2016 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that differential production of IL-10 might be a factor in the severity of MS.
|
14616291 |
2003 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results prove a minor role of IL-10 in the autoimmune diabetes risk, although we found the same association trend with IL-10G(*)12 allele as was previously observed for multiple sclerosis and rheumatoid arthritis.
|
15057267 |
2004 |